Press Room
Inhalation Drug Delivery: The Impact of Particle Size Reduction
Pharmaceutical Technology, September 2, 2019
Within the past few years, much has been learned about characterizing the particles used in inhalation therapies, with the goal of improving drug delivery to the lungs.
Optimizing the manufacturing of these therapies requires avoiding particle interactions during size reducing, blending, and capsule filling, because these can affect the final product鈥檚 quality.听
In an inhalation formulation, the听physicochemical properties of size-reduced drug particles strongly affect听the end product鈥檚 stability and performance. Previous studies reported that size-reduced APIs that had been milled using different techniques may present significant differences in terms of morphological and interfacial properties (1,2). Characterizing the particles鈥 surface properties is key to understanding API/excipient interactions and their impact on the final formulation performance.听
Selecting the micronization technique is crucial for particles that are to be used in inhalation therapies, because it will determine the API鈥檚 properties. For inhalation delivery, a narrow and controlled particle size distribution (PSD) is key to improving and consistently delivering the aerodynamic performance. With a narrow PSD and Dv90
听
听
